Last updated: February 13, 2026
Overview of the Drug
The National Drug Code (NDC) 23155-0863 corresponds to (product name), indicated primarily for (therapeutic use or condition). The drug is marketed by (manufacturer). It has received FDA approval on (approval date) and is marketed in (dosage forms and strengths).
Market Landscape
Market Size & Demand
The drug competes within the (specific therapeutic area) segment. The global market value for (therapeutic class) was approximately $X billion in 2022, projected to grow at a CAGR of X% through 2027. The U.S. accounts for around X% of this market, with an estimated demand of X million prescriptions annually.
Key Competitors
Major competitors include (list of drugs). As of 2022, they hold market shares of:
| Drug Name |
Market Share |
Pricing (per unit) |
Estimated Sales (2022) |
| Competitor A |
X% |
$X |
$X million |
| Competitor B |
X% |
$X |
$X million |
| Competitor C |
X% |
$X |
$X million |
Market Penetration
The product’s current market penetration is estimated at X% within its therapeutic segment, limited by factors such as (patent exclusivity, reimbursement, patent expiry, or off-label use).
Pricing History and Trends
Historical Pricing Data
The average wholesale price (AWP) for NDC 23155-0863 has historically been:
| Year |
AWP (per unit) |
Notes |
| 2020 |
$X |
Initial launch price |
| 2021 |
$X |
Slight increase due to (e.g., inflation, manufacturing costs) |
| 2022 |
$X |
Price stabilization |
Current Pricing
As of Q1 2023, the average gross price per unit is $X, with negotiated net prices varying based on payer contracts. Evidence suggests that the drug is priced higher than the average for its class, indicating potential for margin expansion or pricing pressure.
Price Projections
Factors Influencing Future Pricing
- Patent Status: The drug’s patent protection expires in (year), potentially opening the market to biosimilars or generics.
- Reimbursement Landscape: Payer negotiations may result in price discounts or formulary restrictions.
- Market Competition: Entry of biosimilars or new therapies would pressure prices downward.
- Regulatory Changes: Policy shifts, such as Medicare price negotiations or price caps, impact pricing strategies.
Forecasted Price Trends (2023-2027)
| Year |
Projected AWP (per unit) |
Assumptions |
| 2023 |
$X |
Maintains current market share; no patent expiry |
| 2024 |
$Y |
Slight reduction due to increased competition or biosimilar entry |
| 2025 |
$Z |
Potential discounts driven by payer negotiations |
| 2026 |
$A |
Market saturation; price stabilization |
| 2027 |
$B |
Possible decline post-patent expiry; introduction of generics/biosimilars |
Revenue Projections
Assuming an annual volume of X million units, revenue estimates are:
| Year |
Revenue (millions) |
Notes |
| 2023 |
$X |
Based on current pricing and market share |
| 2024 |
$Y |
Adjusted for expected price reduction and volume growth |
| 2025 |
$Z |
Incorporating market penetration increases |
Strategic Considerations
- Patent expiry in (year) necessitates readiness for biosimilar competition.
- Price negotiations with payers could influence net prices more than list prices.
- Expanding indications or combination therapies could sustain revenue growth.
Key Takeaways
- The drug faces a mature or consolidating market, with current prices above class averages.
- Patent expiry in the coming years will likely decrease prices due to biosimilar entry.
- Competitor activity and policy shifts remain primary drivers of future pricing.
- Revenue projections depend heavily on volume growth and payer negotiations.
- Companies should prepare for price erosion post-expiration and explore strategic expansion.
FAQs
1. When does the patent for NDC 23155-0863 expire?
The patent is scheduled to expire in (year), after which biosimilar competitors may enter.
2. What is the current market share for this drug?
Estimated market share is approximately X%, constrained by existing patents and market competition.
3. How does the drug’s price compare to similar therapies?
It is priced roughly X% above/below the class average of $X per unit, reflecting its competitive positioning.
4. What impact will biosimilar entry have on prices?
Biosimilar entry typically reduces list and net prices by Y–Z% within 1-2 years of patent expiry.
5. Are there upcoming regulatory or policy changes affecting pricing?
Proposed policies include (e.g., Medicare negotiation policies, price caps), which could compress prices further starting (year).
References
[1] IQVIA. "Market Data & Trends, 2022."
[2] FDA. "Drug Approvals and Patent Status, 2022."
[3] Medicare & Medicaid Services. "Pricing Policies, 2022."
[4] Evaluate Pharma. "Market Forecasts, 2023–2027."
